je.st
news
Tag: treatment
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda (pembrolizumab) as First-line Treatment for Advanced Melanoma
2015-10-13 13:30:03| Merck.com - Product News
Dateline City: WILMINGTON, Del. and KENILWORTH, N.J. Pivotal study to evaluate Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with advanced or metastatic melanoma WILMINGTON, Del. and KENILWORTH, N.J. -- Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incytes investigational selective IDO1 inhibitor, with Keytruda (pembrolizumab), Mercks anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. Language: English read more
Tags: for
advanced
include
study
Excelitas and Enercon Hosting UV LED Curing & Plasma Treatment Webinar October 15
2015-10-12 07:00:00| Coatings World Breaking News
Tags: october
treatment
led
hosting
KEYTRUDA (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
2015-10-09 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-236-1130orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
advanced
health
care
Ridgefield giant progresses on psoriasis treatment
2015-10-08 16:10:57| Biotech - Topix.net
Boehringer Ingelheim Pharmaceuticals reported results from a trial of an injectable drug candidate to clear psoriasis, saying it cleared skin faster and for a longer duration than an existing treatment on the market. Boehringer Ingelheim is based in Germany and has its U.S. headquarters in Ridgefield.
Tags: treatment
giant
progresses
psoriasis
Linde Oxygen Booster Cuts Soluble BOD after or before DAF Treatment
2015-10-08 12:31:14| Industrial Newsroom - All News for Today
When Organic Wastewater Treatment Needs a Boost MURRAY HILL, N.J. and NEW PROVIDENCE, N.J. - A custom oxygen booster system from Linde LLC, known as the SOLVOX oxygenation system, proved effective in dramatically lowering biochemical oxygen demand (BOD) for an on-site wastewater treatment facility for Koch Foods...
Tags: treatment
cuts
oxygen
soluble
Sites : [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] next »